The global clinical microbiology market size is expected to reach USD 16.7 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 6.7% over the forecast period. Clinical microbiology depends on technical and skilled workforce to process and interpret results of clinical specimens. Clinical staff has been complaining about poor Turnaround Time (TAT) of tests. However, with technological advancements, a number of laboratory instruments and equipment are being replaced with automated devices to minimize human error and dependency on skilled workforce. In addition, automation has benefits such as reduced TAT and use of labor and lab space, thereby reducing overall cost associated with these tests. Manufacturers are focusing on introduction of automatic specimen processing, plate reading, and organism identification. GE Healthcare, PerkinElmer, and Thermo Fisher are some of the key players offering automated systems in the diagnostics industry. Rising cases of hospital-acquired infections (HAI) is also fueling demand for clinical microbiology for diagnosis and monitoring. As high-income countries are stepping up their pursuit of countering hospital-acquired infections, middle- and low-income countries are recognizing the threat. Introduction of automated systems and innovative designs is expected to intensify market competition and change market dynamics over the forecast period.

North America is relied upon to overwhelm the clinical microbiology showcase in 2018. Topographically, the market is fragmented into North America (the US and Canada), Europe (Germany, the UK, France, and the Rest of Europe), Asia Pacific (Japan, China, India, and the Rest of APAC), and the Rest of the World (Latin America, and the Middle East and Africa). North America is relied upon to represent the biggest offer of the worldwide clinical microbiology advertise in 2018 because of simple availability and high reception of cutting edge demonstrative procedures, mechanical headways in microbial testing systems, rising geriatric populace, and developing open private financing to help microbiology-based research in the area. The real players working in the microbiology testing/clinical microbiology advertise incorporate bioMérieux SA (France), Danaher Corporation (US), Becton, Dickinson and Company (US), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Bruker Corporation (US), Hologic, Inc. (US), QIAGEN N.V. (The Netherlands), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Shimadzu Corporation (Japan), 3M Company (US), and Neogen Corporation (US), among others.